Ivermectin Role in COVID-19 Treatment (IRICT): single center, adaptive, randomized, double-blind, placebo controlled, clinical trial

{ 'indexed': {'date-parts': [[2022, 7, 7]], 'date-time': '2022-07-07T16:13:19Z', 'timestamp': 1657210399413}, 'reference-count': 46, 'publisher': 'Informa UK Limited', 'content-domain': {'domain': ['www.tandfonline.com'], 'crossmark-restriction': True}, 'DOI': '10.1080/14787210.2022.2098113', 'type': 'journal-article', 'created': {'date-parts': [[2022, 7, 5]], 'date-time': '2022-07-05T06:51:38Z', 'timestamp': 1657003898000}, 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Ivermectin Role in COVID-19 Treatment (IRICT): single center, adaptive, randomized, ' 'double-blind, placebo controlled, clinical trial', 'prefix': '10.1080', 'author': [ { 'given': 'Ahmed Hanei', 'family': 'Elshafie', 'sequence': 'first', 'affiliation': [ { 'name': 'Neurology and psychiatry department, Shebin Elkom teaching ' 'hospital, Menoufia university, Shebin Elkom, Menoufia, Egypt'}]}, { 'given': 'Hozaifa Khalil', 'family': 'Elsawah', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of biostatistics, high institute of public health, ' 'Alexandria university, Alexandria, Egypt'}]}, { 'given': 'Mohamed', 'family': 'Hammad', 'sequence': 'additional', 'affiliation': [ { 'name': 'Neurology and psychiatry department, Shebin Elkom teaching ' 'hospital, Menoufia university, Shebin Elkom, Menoufia, Egypt'}]}, { 'ORCID': 'http://orcid.org/0000-0003-3689-2648', 'authenticated-orcid': False, 'given': 'Eman Mohamed', 'family': 'Sweed', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical pharmacology department, Faculty of Medicine, Menoufia ' 'university, Shebin Elkom, Menoufia, Egypt'}]}, { 'given': 'Ahmed Salah', 'family': 'Seif', 'sequence': 'additional', 'affiliation': [ { 'name': 'Gastrohepatology and endemic medicine department, Shebin Elkom ' 'teaching hospital, Menoufia university, Shebin Elkom, Menoufia, ' 'Egypt'}]}, { 'given': 'Muhammad Mostafa', 'family': 'Abdel Ghaffar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Gastrohepatology and endemic medicine department, Ahmed Maher ' 'teaching hospital, Cairo, Egypt'}]}, { 'given': 'Feisal Mahmoud', 'family': 'Goda', 'sequence': 'additional', 'affiliation': [ { 'name': 'General surgery department, Shebin Elkom teaching hospital, ' 'Menoufia university, Shebin Elkom, Menoufia, Egypt'}]}, { 'given': 'Esraa M', 'family': 'Mosalam', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Biochemistry, Faculty of Pharmacy, Menoufia ' 'University, Shebin El-Kom, Egypt'}]}, { 'ORCID': 'http://orcid.org/0000-0002-3237-1792', 'authenticated-orcid': False, 'given': 'Mahmoud S.', 'family': 'Abdallah', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Pharmacy Department, Faculty of Pharmacy, University of ' 'Sadat City (USC), Sadat City, Menoufia, 32897, Egypt'}]}], 'member': '301', 'published-online': {'date-parts': [[2022, 7, 4]]}, 'reference': [ { 'key': 'cit0001', 'doi-asserted-by': 'crossref', 'unstructured': '1.\tAltay O, Mohammadi E, Lam S, et al. Current Status of COVID-19 ' 'Therapies and Drug Repositioning Applications. Iscience. 2020 Jul;23(7).', 'DOI': '10.1016/j.isci.2020.101303'}, { 'key': 'cit0002', 'unstructured': '2.\tWoldometers. COVID-19 CORONAVIRUS PANDEMIC 2022 [cited 2022 8 ' 'January]. Available from: https://www.worldometers.info/coronavirus/'}, { 'key': 'cit0003', 'doi-asserted-by': 'crossref', 'unstructured': '3.\tMudatsir M, Fajar JK, Wulandari L, et al. Predictors of COVID-19 ' 'severity: a systematic review and meta-analysis. F1000Research. ' '2020;9:1107-1107.', 'DOI': '10.12688/f1000research.26186.1'}, { 'key': 'cit0004', 'doi-asserted-by': 'crossref', 'unstructured': '4.\tvan Eijk LE, Binkhorst M, Bourgonje AR, et al. COVID‐19: ' 'immunopathology, pathophysiological mechanisms, and treatment options. ' 'The Journal of Pathology. 2021.', 'DOI': '10.1002/path.5642'}, { 'key': 'cit0005', 'doi-asserted-by': 'crossref', 'unstructured': '5.\tRizk JG, Kalantar-Zadeh K, Mehra MR, et al. ' 'Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020:1-26.', 'DOI': '10.1016/j.drudis.2020.11.025'}, { 'key': 'cit0006', 'doi-asserted-by': 'crossref', 'unstructured': '6.\tFerri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic ' 'autoimmune systemic diseases: report of a large Italian patients series. ' 'Clinical Rheumatology. 2020;39(11):3195-3204.', 'DOI': '10.1007/s10067-020-05334-7'}, { 'key': 'cit0007', 'doi-asserted-by': 'crossref', 'unstructured': '7.\tMurdaca G, Spanò F, Contatore M, et al. Pharmacogenetics of ' 'etanercept: role of TNF-α gene polymorphisms in improving its efficacy. ' 'Expert opinion on drug metabolism & toxicology. 2014;10(12):1703-1710.', 'DOI': '10.1517/17425255.2014.970165'}, { 'key': 'cit0008', 'doi-asserted-by': 'crossref', 'unstructured': '8.\tGuy RK, DiPaola RS, Romanelli F, et al. Rapid repurposing of drugs ' 'for COVID-19. Science. 2020 May;368(6493):829-+.', 'DOI': '10.1126/science.abb9332'}, { 'key': 'cit0009', 'doi-asserted-by': 'crossref', 'unstructured': '9.\tHossain MJ, Rahman SMA. Repurposing therapeutic agents against ' 'SARS-CoV-2 infection: most promising and neoteric progress. Expert Rev ' 'Anti Infect Ther. 2021 Aug;19(8):1009-1027.', 'DOI': '10.1080/14787210.2021.1864327'}, { 'key': 'cit0010', 'doi-asserted-by': 'crossref', 'unstructured': '10.\tRainsford K, Parke AL, Clifford-Rashotte M, et al. Therapy and ' 'pharmacological properties of hydroxychloroquine and chloroquine in ' 'treatment of systemic lupus erythematosus, rheumatoid arthritis and ' 'related diseases. Inflammopharmacology. 2015;23(5):231-269.', 'DOI': '10.1007/s10787-015-0239-y'}, { 'key': 'cit0011', 'doi-asserted-by': 'crossref', 'unstructured': '11.\tElsawah HK, Elsokary MA, Elrazzaz MG, et al. Hydroxychloroquine for ' 'treatment of nonsevere COVID‐19 patients: Systematic review and ' 'meta‐analysis of controlled clinical trials. Journal of medical ' 'virology. 2021;93(3):1265-1275.', 'DOI': '10.1002/jmv.26442'}, { 'key': 'cit0012', 'unstructured': '12.\tAxfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with ' 'hydroxychloroquine and chloroquine in COVID-19 from an international ' 'collaborative meta-analysis of randomized trials. Nature communications. ' '2021;12(1):1-13.'}, { 'key': 'cit0013', 'doi-asserted-by': 'crossref', 'unstructured': '13.\tStrycharz JP, Yoon KS, Clark JM. A new ivermectin formulation ' 'topically kills permethrin-resistant human head lice (Anoplura: ' 'Pediculidae). Journal of Medical Entomology. 2008 Jan;45(1):75-81.', 'DOI': '10.1093/jmedent/45.1.75'}, { 'key': 'cit0014', 'doi-asserted-by': 'crossref', 'unstructured': '14.\tGeary TG. Ivermectin 20 years on: maturation of a wonder drug. ' 'Trends in Parasitology. 2005 Nov;21(11):530-532.', 'DOI': '10.1016/j.pt.2005.08.014'}, { 'key': 'cit0015', 'doi-asserted-by': 'crossref', 'unstructured': '15.\tMuñoz J, Ballester MR, Antonijoan RM, et al. Safety and ' 'pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg ' 'tablet in healthy adult volunteers. PLoS Negl Trop Dis. ' '2018;12(1):e0006020-e0006020.', 'DOI': '10.1371/journal.pntd.0006020'}, { 'key': 'cit0016', 'doi-asserted-by': 'crossref', 'unstructured': '16.\tRizzo E. Ivermectin, antiviral properties and COVID-19: a possible ' 'new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. 2020 ' 'Jul;393(7):1153-1156.', 'DOI': '10.1007/s00210-020-01902-5'}, { 'key': 'cit0017', 'doi-asserted-by': 'crossref', 'unstructured': '17.\tJans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. ' 'Current Opinion in Cell Biology. 2019 Jun;58:50-60.', 'DOI': '10.1016/j.ceb.2019.01.001'}, { 'key': 'cit0018', 'doi-asserted-by': 'crossref', 'unstructured': '18.\tCaly L, Druce JD, Catton MG, et al. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'Research. 2020 Jun;178.', 'DOI': '10.1016/j.antiviral.2020.104787'}, { 'key': 'cit0019', 'doi-asserted-by': 'crossref', 'unstructured': '19.\tMudatsir M, Yufika A, Nainu F, et al. Antiviral Activity of ' 'Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A ' 'Literature Review. Scientia Pharmaceutica. 2020;88(3).', 'DOI': '10.3390/scipharm88030036'}, { 'key': 'cit0020', 'doi-asserted-by': 'crossref', 'unstructured': '20.\tKaur H, Shekhar N, Sharma S, et al. Ivermectin as a potential drug ' 'for treatment of COVID-19: an in-sync review with clinical and ' 'computational attributes. Pharmacol Rep. 2021 Jan 3:1-14.', 'DOI': '10.1007/s43440-020-00195-y'}, { 'key': 'cit0021', 'doi-asserted-by': 'crossref', 'unstructured': '21.\tHellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence ' 'associated with prophylactic administration of ivermectin. Int J ' 'Antimicrob Agents. 2021 Jan;57(1):106248.', 'DOI': '10.1016/j.ijantimicag.2020.106248'}, { 'key': 'cit0022', 'doi-asserted-by': 'crossref', 'unstructured': '22.\tde Melo GD, Lazarini F, Larrous F, et al. Anti-COVID-19 efficacy of ' 'ivermectin in the golden hamster. bioRxiv. 2020:2020.11.21.392639.', 'DOI': '10.1101/2020.11.21.392639'}, { 'key': 'cit0023', 'doi-asserted-by': 'crossref', 'unstructured': '23.\tAhmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin ' 'for the treatment of COVID-19 may reduce the duration of illness. Int J ' 'Infect Dis. 2020 Dec 2;103:214-216.', 'DOI': '10.1016/j.ijid.2020.11.191'}, { 'key': 'cit0024', 'doi-asserted-by': 'crossref', 'unstructured': '24.\tSoto-Becerra P, Culquichicón C, Hurtado-Roca Y, et al. Real-world ' 'effectiveness of hydroxychloroquine, azithromycin, and ivermectin among ' 'hospitalized COVID-19 patients: results of a target trial emulation ' 'using observational data from a nationwide healthcare system in Peru. ' 'medRxiv. 2020:2020.10.06.20208066.', 'DOI': '10.1101/2020.10.06.20208066'}, { 'key': 'cit0025', 'unstructured': '25.\tInstitutes N, Health o. Coronavirus disease 2019 (COVID-19) ' 'treatment guidelines. 2021.'}, { 'key': 'cit0026', 'doi-asserted-by': 'crossref', 'unstructured': '26.\tGroup RC. Dexamethasone in hospitalized patients with Covid-19. New ' 'England Journal of Medicine. 2021;384(8):693-704.', 'DOI': '10.1056/NEJMoa2021436'}, { 'key': 'cit0027', 'doi-asserted-by': 'crossref', 'unstructured': '27.\tHill A, Abdulamir A, Ahmed S, et al. Meta-analysis of randomized ' 'trials of ivermectin to treat SARS-CoV-2 infection. 2021.', 'DOI': '10.1093/ofid/ofab358'}, { 'key': 'cit0028', 'doi-asserted-by': 'crossref', 'unstructured': '28.\tGautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and ' 'azithromycin as a treatment of COVID-19: results of an open-label ' 'non-randomized clinical trial. International journal of antimicrobial ' 'agents. 2020;56(1):105949.', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': 'cit0029', 'doi-asserted-by': 'crossref', 'unstructured': '29.\tChristensen E. Methodology of superiority vs. equivalence trials ' 'and non-inferiority trials. Journal of hepatology. 2007;46(5):947-954.', 'DOI': '10.1016/j.jhep.2007.02.015'}, { 'key': 'cit0030', 'doi-asserted-by': 'crossref', 'unstructured': '30.\tNjoo F, Hack C, Oosting J, et al. C-reactive protein and ' 'interleukin-6 are elevated in onchocerciasis patients after ivermectin ' 'treatment. Journal of Infectious Diseases. 1994;170(3):663-668.', 'DOI': '10.1093/infdis/170.3.663'}, { 'key': 'cit0031', 'doi-asserted-by': 'crossref', 'unstructured': '31.\tCoyne PE, Addiss DG. Deaths associated with ivermectin for scabies. ' 'The Lancet. 1997;350(9072):215-216.', 'DOI': '10.1016/S0140-6736(05)62378-1'}, { 'key': 'cit0032', 'doi-asserted-by': 'crossref', 'unstructured': '32.\tMackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in ' 'the adverse clinical events seen following ivermectin administration to ' 'onchocerciasis patients. Filaria journal. 2003;2(1):1-9.', 'DOI': '10.1186/1475-2883-2-S1-S5'}, { 'key': 'cit0033', 'doi-asserted-by': 'crossref', 'unstructured': '33.\tKudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 ' 'and CYP3A5 genes in a Ghanaian population: a plausible explanation for ' 'altered metabolism of ivermectin in humans? BMC medical genetics. ' '2010;11(1):1-8.', 'DOI': '10.1186/1471-2350-11-111'}, { 'key': 'cit0034', 'doi-asserted-by': 'crossref', 'unstructured': '34.\tChandler RE. Serious neurological adverse events after ' 'ivermectin—do they occur beyond the indication of onchocerciasis? The ' 'American journal of tropical medicine and hygiene. 2018;98(2):382.', 'DOI': '10.4269/ajtmh.17-0042'}, { 'key': 'cit0035', 'unstructured': '35.\tSherif W, Mohamed M. E, Ibrahim H. E. Egyptian National guidelines ' 'for COVID -19 2020.'}, { 'key': 'cit0036', 'doi-asserted-by': 'crossref', 'unstructured': '36.\tRakedzon S, Neuberger A, Domb A, et al. From hydroxychloroquine to ' 'ivermectin: what are the anti-viral properties of anti-parasitic drugs ' 'to combat SARS-CoV-2? Journal of Travel Medicine. 2021;28(2):taab005.', 'DOI': '10.1093/jtm/taab005'}, { 'key': 'cit0037', 'doi-asserted-by': 'crossref', 'unstructured': '37.\tHong TS, Gonzalez J, Nahass RG, et al. Impact of Hydroxychloroquine ' 'on Mortality in Hospitalized Patients with COVID-19: Systematic Review ' 'and Meta-Analysis. Pharmacy. 2020;8(4):208.', 'DOI': '10.3390/pharmacy8040208'}, { 'key': 'cit0038', 'doi-asserted-by': 'crossref', 'unstructured': '38.\tYao X, Ye F, Zhang M, et al. In vitro antiviral activity and ' 'projection of optimized dosing design of hydroxychloroquine for the ' 'treatment of severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2). Clinical infectious diseases. 2020;71(15):732-739.', 'DOI': '10.1093/cid/ciaa237'}, { 'key': 'cit0039', 'doi-asserted-by': 'crossref', 'unstructured': '39.\tTett S, Cutler D, Day R, et al. Bioavailability of ' 'hydroxychloroquine tablets in healthy volunteers. British journal of ' 'clinical pharmacology. 1989;27(6):771-779.', 'DOI': '10.1111/j.1365-2125.1989.tb03439.x'}, { 'key': 'cit0040', 'doi-asserted-by': 'crossref', 'unstructured': '40.\tOttesen EA, Campbell W. Ivermectin in human medicine. Journal of ' 'antimicrobial chemotherapy. 1994;34(2):195-203.', 'DOI': '10.1093/jac/34.2.195'}, { 'key': 'cit0041', 'unstructured': '41.\tMerck Statement on Ivermectin use During the COVID-19 Pandemic 2021 ' '[cited 2021 June]. Available from: ' 'https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/'}, { 'key': 'cit0042', 'unstructured': '42.\tPLAQUENIL: Sanofi 2017 [cited 2021 June]. Available from: ' 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf'}, { 'key': 'cit0043', 'doi-asserted-by': 'crossref', 'unstructured': '43.\tReardon S. Flawed ivermectin preprint highlights challenges of ' 'COVID drug studies. Nature. 2021;596(7871):173-174.', 'DOI': '10.1038/d41586-021-02081-w'}, { 'key': 'cit0044', 'unstructured': '44.\tAdministration FDA. Why You Should Not Use Ivermectin to Treat or ' 'Prevent COVID-19? 2021 [cited 2021 12/8/2021]. Available from: ' 'https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19'}, { 'key': 'cit0045', 'doi-asserted-by': 'crossref', 'unstructured': '45.\tPeña‐Silva R, Duffull SB, Steer AC, et al. Pharmacokinetic ' 'considerations on the repurposing of ivermectin for treatment of ' 'COVID‐19. British Journal of Clinical Pharmacology. 2020.', 'DOI': '10.1111/bcp.14476'}, { 'key': 'cit0046', 'doi-asserted-by': 'crossref', 'unstructured': '46.\tDuenas-Gonzalez A. The pharmacokinetic rationale of Ivermectin for ' 'COVID-19 therapy. Authorea Preprints. 2021.', 'DOI': '10.22541/au.163513079.90720371/v1'}], 'container-title': 'Expert Review of Anti-infective Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/14787210.2022.2098113', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 7, 5]], 'date-time': '2022-07-05T06:51:59Z', 'timestamp': 1657003919000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.tandfonline.com/doi/full/10.1080/14787210.2022.2098113'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7, 4]]}, 'references-count': 46, 'alternative-id': ['10.1080/14787210.2022.2098113'], 'URL': 'http://dx.doi.org/10.1080/14787210.2022.2098113', 'relation': {}, 'ISSN': ['1478-7210', '1744-8336'], 'subject': ['Virology', 'Infectious Diseases', 'Microbiology (medical)', 'Microbiology'], 'container-title-short': 'Expert Review of Anti-infective Therapy', 'published': {'date-parts': [[2022, 7, 4]]}, 'assertion': [ { 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.', 'order': 1, 'name': 'peerreview_statement', 'label': 'Peer Review Statement'}, { 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierz20', 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierz20', 'order': 2, 'name': 'aims_and_scope_url', 'label': 'Aim & Scope'}, { 'value': '2021-11-12', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-05-04', 'order': 1, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-06-17', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-07-04', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}